DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 202 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $97 | +16.9% | 4,192 | +4.2% | 0.00% | 0.0% |
Q1 2024 | $83 | -77.3% | 4,024 | -76.4% | 0.00% | -66.7% |
Q4 2023 | $366 | -2.9% | 17,057 | -6.6% | 0.00% | 0.0% |
Q3 2023 | $377 | -27.4% | 18,255 | +3.9% | 0.00% | -25.0% |
Q2 2023 | $519 | +46.6% | 17,576 | +14.3% | 0.00% | +33.3% |
Q1 2023 | $354 | -29.1% | 15,380 | -14.4% | 0.00% | -25.0% |
Q4 2022 | $499 | -99.9% | 17,959 | +12.7% | 0.00% | -20.0% |
Q3 2022 | $489,000 | +6.8% | 15,942 | +2.4% | 0.01% | +25.0% |
Q2 2022 | $458,000 | -4.4% | 15,562 | +4.5% | 0.00% | 0.0% |
Q1 2022 | $479,000 | -66.5% | 14,893 | -53.5% | 0.00% | -20.0% |
Q4 2021 | $1,428,000 | +75.0% | 32,024 | +97.9% | 0.01% | -28.6% |
Q3 2021 | $816,000 | -39.5% | 16,184 | -5.8% | 0.01% | -36.4% |
Q2 2021 | $1,348,000 | +163.8% | 17,181 | +91.9% | 0.01% | -42.1% |
Q1 2021 | $511,000 | -37.9% | 8,953 | -8.9% | 0.02% | -38.7% |
Q4 2020 | $823,000 | +135.1% | 9,828 | +0.5% | 0.03% | +106.7% |
Q3 2020 | $350,000 | +44.0% | 9,779 | -2.8% | 0.02% | +36.4% |
Q2 2020 | $243,000 | – | 10,064 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |